Sarcoma  >>  indoximod (NLG8189)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
indoximod (NLG8189) / Lumos Pharma
NCT02502708: Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

Checkmark From trial for front-line DIPG at ESMO-IO 2019
Dec 2019 - Dec 2019: From trial for front-line DIPG at ESMO-IO 2019
Checkmark Data in combination with radiation and chemotherapy for children with diffuse intrinsic pontine glioma at ISPNO
Jul 2018 - Jul 2018: Data in combination with radiation and chemotherapy for children with diffuse intrinsic pontine glioma at ISPNO
Checkmark In pediatric brain cancer at AACR 2018
More
Completed
1
81
US
Indoximod, 1-methyl-D-tryptophan, D-1MT, Temozolomide, Temodar, Methazolastone, Conformal Radiation, Cyclophosphamide, Etoposide
NewLink Genetics Corporation
Glioblastoma Multiforme, Glioma, Gliosarcoma, Malignant Brain Tumor, Ependymoma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma, Primary CNS Tumor
12/19
02/20

Download Options